These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30584916)

  • 1. Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
    Schwermer M; Hiber M; Dreesmann S; Rieb A; Theißen J; Herold T; Schramm A; Temming P; Steenpass L
    Exp Cell Res; 2019 Feb; 375(2):92-99. PubMed ID: 30584916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma.
    Ewens KG; Bhatti TR; Moran KA; Richards-Yutz J; Shields CL; Eagle RC; Ganguly A
    Cancer Med; 2017 Mar; 6(3):619-630. PubMed ID: 28211617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of high level E2F in a RB1 proficient MYCN overexpressing chicken retinoblastoma model normalizes neoplastic behaviour.
    Zhang H; Konjusha D; Rafati N; Tararuk T; Hallböök F
    Cell Oncol (Dordr); 2024 Feb; 47(1):209-227. PubMed ID: 37606819
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Price EA; Patel R; Scheimberg I; Kotiloglu Karaa E; Sagoo MS; Reddy MA; Onadim Z
    Ophthalmic Genet; 2021 Oct; 42(5):604-611. PubMed ID: 34003079
    [No Abstract]   [Full Text] [Related]  

  • 5.
    De Rosa P; Severi F; Zadran SK; Russo M; Aloisi S; Rigamonti A; Capranico G; Milazzo G; Perini G
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of MYCN in retinoblastoma: A review of current literature.
    Vempuluru VS; Maniar A; Bakal K; Kaliki S
    Surv Ophthalmol; 2024; 69(5):697-706. PubMed ID: 38796108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI Features for Identifying
    Jansen RW; de Bloeme CM; Cardoen L; Göricke S; van Elst S; Jessen JL; Ramasubramanian A; Skalet AH; Miller AK; Maeder P; Uner OE; Hubbard GB; Grossniklaus H; Boldt HC; Nichols KE; Brennan RC; Sen S; Sirin S; Brisse HJ; Galluzzi P; Dommering CJ; Castelijns JA; van der Valk P; Boellaard R; Dorsman J; Moll AC; de Jong MC; de Graaf P
    Radiology; 2023 Jun; 307(5):e222264. PubMed ID: 37191489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
    Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
    Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary enucleated retinoblastoma with MYCN amplification.
    Moulin AP; Stathopoulos C; Marcelli F; Schoumans Pouw J; Beck-Popovic M; Munier FL
    Ophthalmic Genet; 2021 Jun; 42(3):354-359. PubMed ID: 33870828
    [No Abstract]   [Full Text] [Related]  

  • 10. Silencing of the Long Noncoding RNA MYCNOS1 Suppresses Activity of MYCN-Amplified Retinoblastoma Without RB1 Mutation.
    Saengwimol D; Chittavanich P; Laosillapacharoen N; Srimongkol A; Chaitankar V; Rojanaporn D; Aroonroch R; Suktitipat B; Saisawang C; Svasti S; Hongeng S; Kaewkhaw R
    Invest Ophthalmol Vis Sci; 2020 Dec; 61(14):8. PubMed ID: 33270844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous identification of clinically relevant
    Xu L; Shen L; Polski A; Prabakar RK; Shah R; Jubran R; Kim JW; Biegel J; Kuhn P; Cobrinik D; Hicks J; Gai X; Berry JL
    Ophthalmic Genet; 2020 Dec; 41(6):526-532. PubMed ID: 32799607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.
    Rushlow DE; Mol BM; Kennett JY; Yee S; Pajovic S; Thériault BL; Prigoda-Lee NL; Spencer C; Dimaras H; Corson TW; Pang R; Massey C; Godbout R; Jiang Z; Zacksenhaus E; Paton K; Moll AC; Houdayer C; Raizis A; Halliday W; Lam WL; Boutros PC; Lohmann D; Dorsman JC; Gallie BL
    Lancet Oncol; 2013 Apr; 14(4):327-34. PubMed ID: 23498719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-Generation Sequencing of Retinoblastoma Identifies Pathogenic Alterations beyond RB1 Inactivation That Correlate with Aggressive Histopathologic Features.
    Afshar AR; Pekmezci M; Bloomer MM; Cadenas NJ; Stevers M; Banerjee A; Roy R; Olshen AB; Van Ziffle J; Onodera C; Devine WP; Grenert JP; Bastian BC; Solomon DA; Damato BE
    Ophthalmology; 2020 Jun; 127(6):804-813. PubMed ID: 32139107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
    Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
    Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of germline mutations in RB1 in Chinese patients with retinoblastoma: Application of targeted next-generation sequencing.
    Zou Y; Li J; Hua P; Liang T; Ji X; Zhao P
    Mol Vis; 2021; 27():1-16. PubMed ID: 33456302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations in retinoblastoma beyond RB1.
    Mendonça V; Evangelista AC; P Matta B; M Moreira MÂ; Faria P; Lucena E; Seuánez HN
    Exp Eye Res; 2021 Oct; 211():108753. PubMed ID: 34478740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
    Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
    Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel insights into RB1 mutation.
    Yao Y; Gu X; Xu X; Ge S; Jia R
    Cancer Lett; 2022 Oct; 547():215870. PubMed ID: 35964818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The
    Berry JL; Polski A; Cavenee WK; Dryja TP; Murphree AL; Gallie BL
    Genes (Basel); 2019 Nov; 10(11):. PubMed ID: 31683923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.